Adding lenvatinib to immunotherapy for liver cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests adding lenvatinib (a targeted therapy pill) to a combination of two immunotherapy drugs (durvalumab and tremelimumab) for people with liver cancer that cannot be removed by surgery. The goal is to see if the three-drug approach works better than the two immunotherapy drugs alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and weigh more than 66 pounds.
- Your liver cancer has not spread to other parts of the body and can be measured on a scan.
- You have not had any previous whole-body treatments for liver cancer.
- Your liver function is good enough (a Child-Pugh score of A or B) and your overall health allows for daily activities (ECOG 0 or 1).
- If you have hepatitis B or C, it must be stable and you may need treatment during the study.
- You are willing to use effective birth control and avoid donating blood for several months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of a procedure that delivers chemotherapy directly to the liver tumor (called TACE) with an oral targeted therapy drug (lenvatinib) for people with liver cancer that cannot be removed with surgery. The goal is to see if this combination can shrink tumors more effectively than TACE alone.
This study tests a combination of two drugs—lenvatinib (a targeted therapy that blocks blood vessel growth) and tislelizumab (an immunotherapy that helps your immune system fight cancer)—in people with advanced liver cancer who also have hepatitis B. The goal is to see if this combination can shrink tumors or slow the cancer's growth, and to find biomarkers (clues in your blood or tissue) that predict who will benefit.
This Phase 2 trial tests whether giving lenvatinib and immunotherapy along with TACE (a liver artery treatment) before surgery can lower the risk of hepatocellular carcinoma coming back after surgery. It targets people with certain higher-risk early-stage liver tumors (CNLC IB/IIA).
This Italian study follows patients with advanced liver cancer (hepatocellular carcinoma) who receive a combination immunotherapy treatment called STRIDE for the first time. The trial tracks how well the treatment works, how it affects quality of life, and its safety in people with moderate to severe liver disease.
This trial tests a special type of immune cell therapy (called HBV-TCR T cells) that is designed to attack liver cancer cells that carry the hepatitis B virus. It may be given alone or combined with a pill called lenvatinib to see if it can shrink tumors and help people with advanced liver cancer.
This trial tests a combination of radiation (SBRT), an immunotherapy drug (PD-L1 inhibitor), and a targeted therapy (lenvatinib) for people with liver cancer that has spread to abdominal lymph nodes. It may be an option if you haven't taken certain immunotherapies before or if your cancer progressed after them.
Hear when a new Hepatocellular Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.